Neil Closner – CEO, MedReleaf, Canada
With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO…
Servier Canada Inc is the Canadian affiliate of The Servier Research Group, a leading French research based organisation, specializing in ethical pharmaceuticals.
In the short span of fifty five years, the Servier Research Group has developed in stature from a family-owned, provincial pharmacy employing nine people to a multi-national operation with over 20,000 employees, including 3,000 in R&D, yet the Company is still privately-owned and is still passionately and permanently committed to remaining independent.
In Canada, Servier’s activities commenced in February 1978 in a modest location in Pointe-Claire, Quebec with a total staff of three employees. Within a month of its opening, a Sales supervisor and seven sales representatives were recruited and working in the region of Quebec. From 1985-1991, Servier Canada continued to gradually expand its presence across Canada, with growth in both its size of sales force and the number of head office employees. By 1994, the Company had moved to new premises in Laval, Quebec, where its current facility resides.
Servier Canada is committed to the investment in research and development and was proud to join Canada’s Research Based Pharmaceutical Companies (Rx&D) in 1995.
Contact
With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO…
Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering…
Referring to the Canadian affiliate of Zimmer Biomet as a “trailblazer”, Dave O’Neil looks back on a successful 2017 for the musculoskeletal healthcare company in Canada. He describes how Zimmer…
Looking back on 40 years of commitment to Canada, Servier also celebrates 20 years of R&D activity in the country. On this two-fold anniversary, Frédéric Fasano highlights some of the…
Dwight Gorham, president and CEO of Pillar5 Pharma, discusses the unique positioning of the CDMO in the multi-dose preservative free sterile ophthalmics space and stresses the importance of anticipating market…
Despite its relative youth, Canada’s medical cannabis industry is already presenting some of the characteristics of the much more mature pharmaceutical industry. There is consolidation as well as the first…
Susanne Picard, founder and president at SPharm, speaks about how her passion for regulatory affairs led her to found her own consultancy in 1997 and how the company can look…
Having managed the Canadian affiliate of Otsuka from its infancy steps, Allison Rosenthal, general manager, highlights the affiliate’s feat to exceed expectations for the performance of each of its launches…
Having just announced the first collaboration between a medical cannabis company and a major pharmaceutical player, Tilray expects to launch its first co-branded product with Sandoz Canada by the end…
Looking back on three years of operations in Canada and nine months of approval of Ocaliva® for the rare non-viral liver disease PBC, Brian Canestraro, general manager of Intercept, is…
Lee Ferreira, newly-appointed general manager of Ferring Pharmaceuticals Canada, shares her excitement about the company’s transformative changes. She stresses the importance of conducting research in Canada in all areas of…
After 35 years in the pharmaceutical industry, Barry Fishman shares his excitement about heading one of Canada’s leading licensed cannabis producers. He explains how his experience in the world of…
See our Cookie Privacy Policy Here
